Mostrando 10 resultados de: 14
Publisher
British Journal of Clinical Pharmacology(3)
European Journal of Clinical Pharmacology(2)
Therapeutic Drug Monitoring(2)
Clinical Pharmacology & Therapeutics(1)
Clinical Pharmacology and Therapeutics(1)
Área temáticas
Farmacología y terapéutica(11)
Enfermedades(7)
Medicina y salud(3)
Bioquímica(2)
Ginecología, obstetricia, pediatría, geriatría(2)
Origen
scopus(14)
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
ArticleAbstract: In a previous study we showed that the disposition of clozapine after a single oral dose is unrelatePalabras claves:Autores:Adrián LLerena, Alm C., Benitez Rodriguez J., Bertilsson L., Bondesson U., Carrillo J., Dahl M.L., Lindstrom L., Ramos S., Rodriguez de la Rubia I.Fuentes:scopusAntibiotic use in 3 European university hospitals
ArticleAbstract: The use of antibiotic drugs was studied in university teaching hospitals in Tartu, Estonia, HuddingePalabras claves:Autores:Adrián LLerena, Berecz R., Dahl M.L., Kiivet R.A., Maimets M., Wettermark B.Fuentes:scopusDebrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents
ArticleAbstract: Debrisoquin and S‐mephenytoin hydroxylation phenotypes were determined in 72 Spanish psychiatric patPalabras claves:Autores:Adrián LLerena, Cobaleda J., Dahl M.L., Herraiz A., Johansson I.Fuentes:scopusCYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopusAn Appeal to the Global Health Community for a Tripartite Innovation: An "essential Diagnostics List," "health in All Policies," and "see-Through 21<sup>st</sup> Century Science and Ethics"
ReviewAbstract: Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and naPalabras claves:Autores:Adrián LLerena, Barlas Ö., Birch K., Boehme C., Borda-Rodriguez A., Byne W.M., Chaverneff F., Coşkun Y., Dahl M.L., Dereli T., Diwakar S., Dove E.S., Elbeyli L., Endrenyi L., Eroʇlu-Kesim B., Ferguson L.R., Güngör K., Gürsoy U.K., Hekim N., Huzair F., Kaushik K., Kickbusch I., Klroʇlu O., Kolker E., Könönen E., Lin B., Malhan F., Nair B., Özdemir V., Patrinos G.P., Sardaş S., Sert Ö., Srivastava S., Steuten L.M.G., Toraman C., Vayena E., Wang W., Warnich L.Fuentes:scopusGenetic factors in the metabolism of haloperidol.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusDisposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.
ArticleAbstract: A large interindividual variability has previously been demonstrated in the bioavailability, steady‐Palabras claves:Autores:Adrián LLerena, Bertilsson L., Bondesson U., Dahl M.L., Lindstrom L.Fuentes:scopusDisposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.
ReviewAbstract:Palabras claves:Autores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on debrisoquine hydroxylation phenotype
ArticleAbstract: To investigate the importance of genetic factors for the regulation of haloperidol metabolism, we stPalabras claves:debrisoquine, Haloperidol, humans, pharmacogeneticsAutores:Adrián LLerena, Alm C., Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
ArticleAbstract: We have previously shown that the disposition of haloperidol is decreased in poor (PM) compared to ePalabras claves:debrisoquine, humans, pharmacogenetics, Reduced haloperidolAutores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopus